Presentation

Company Profile
Elekta engages in the business of radiotherapy, providing clinical solutions for the treatment of cancers and brain disorders. The offering includes solutions for radiotherapy, stereotactic radiosurgery, oncology informatics, brachytherapy, neurosurgery, and particle therapy. Elekta is together with the US company Varian the global market leaders in radiotherapy and these two companies have over 90% of the Linac market. Elekta is now about to set a new standard on the Linac market with Unity, incorporating MR Imaging (delivered by Philips) to detect and visualize any geometrical change in patients during treatment.

Recent highlights
In its fourth quarter 2020/21, Feb-Apr 2021, Elekta’s gross order intake increased by 18% y/y in constant currency and amounted to SEK 5,379m (5,032m). Net sales decreased by 9% y/y, amounting to SEK 3,667m (4,008m). EBITA decreased by 16% y/y to SEK 743m (886m), corresponding to a margin of 20.3% (22.1%). Installation volumes were similar to Q4 last year, still impacted by reduced access to hospitals, due to COVID-19. In May, the company announced that it reached the 100th Unity order milestone. In June, Elekta announced that they deepened their strategic partnership with Philips in precise and individualized oncology care.

Outlook
As for the medium-term (up to 2025) Elekta has announced that its new strategy is to focus on growth and access to radiation therapy. Operationally, their focus is to launch a new software platform, to deepen existing and form new partnerships, expand services offering, optimize sales network and establish direct presence in key growth markets, and deliver on science-based sustainability metrics across value chain.